Brentuximab Improves Responses in CTCL Compared to Standard Care

Article

Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.

SAN DIEGO-Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented (abstract 182) at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.

“This is the first report of a randomized phase III trial in CTCL with convincing demonstration of improved efficacy of a new systemic agent over standard-of-care options. BV showed superior primary and secondary efficacy outcomes over methotrexate or bexarotene in mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL). These compelling results have potential practice-changing implications for the use of BV in managing CD-30 expressing CTCL in patients who require systemic therapy,” said lead author Youn H. Kim, MD, an oncologist at Stanford University School of Medicine, Stanford, Calif.

The CD30-directed antibody-drug conjugate BV has demonstrated marked clinical activity in two phase II single-arm trials in CTCL. These results led to a randomized, open-label, multicenter, phase III trial of the efficacy and safety of the drug as compared to physician's choice of methotrexate or bexarotene in 128 previously treated patients with CD30-expressing CTCL.

The MF patients had received one or more prior systemic therapies and the pcALCL patients had received one or more prior systemic therapies or radiotherapy. The patients were randomized to receive BV 1.8 mg/kg IV once every 3 weeks (64 patients) or either methotrexate 5–50 mg orally once weekly or bexarotene 300 mg/m² orally once daily (64 patients) for up to 16 three-week cycles, until disease progression or unacceptable toxicity.

The primary endpoint was ORR lasting 4 or more months (ORR4), an endpoint that captures response rate and duration as a single measurement. “After discussing with experts and the FDA [US Food and Drug Administration], we decided that ORR does not capture meaningful responses. Even complete responses in CTCL are of short duration and not meaningful,” said Kim.

Baseline characteristics of the patients were generally balanced between arms, with the exception of more patients with extracutaneous disease in the BV arm.

At a median follow-up of 17.5 months, ORR4 strongly favored BV (56%) compared to physician’s choice (13%). Median PFS was also superior with BV (16.7 months) than physician’s choice (3.5 months).

A quality-of-life index showed significantly greater symptom reduction with BV compared with physician’s choice.

Patients received a median of 12 cycles of BV vs 5.5 cycles of bexarotene and 3 cycles of methotrexate.

Grade 3–4 adverse events, all-cause/drug-related, were seen in 41%/29% with BV vs 47%/29% with physician’s choice. Serious adverse events were seen in 29% of patients in each arm. As expected, peripheral neuropathy was seen more with BV (67%) than with physician’s choice (6%). At last follow-up, most patients in the BV arm had improvement or resolution of peripheral neuropathy, Kim said.

Discontinuation due to adverse events occurred in 24% in the BV arm and 8% in the physician’s choice arm.

“The data from this randomized trial provide compelling evidence favoring BV over bexarotene or methotrexate in CD30-expressing CTCL,” said Kim.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content